In a recent study following nasal and plasma antibody responses 1 year after COVID-19 hospitalization, individuals who later received an injectable SARS-CoV-2 vaccine mounted systemic IgG and IgA recall responses and nasal IgG responses, but the nasal IgA responses were negligible13. The gene discussed is CD79A; the disease is COVID-19.